Physician profile
Edwin M Quinones
NPI 1902895352
$284.35
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $61.22 | 2019 | |
| Vifor Pharma, INC. | $57.35 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $38.63 | 2019 | |
| Fresenius USA Marketing, INC. | $31.81 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $30.14 | 2019 | |
| Mallinckrodt Enterprises LLC | $19.17 | 2019 | |
| Akebia Therapeutics INC | $17.64 | 2019 | |
| Opko Pharmaceuticals, LLC | $16.62 | 2019 | |
| Daiichi Sankyo INC. | $11.77 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Quinones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.